Company Apricus Biosciences Inc Nasdaq
Equities
US03832V3078
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 86-12-31 |
Director of Finance/CFO | 52 | 18-12-31 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gopal Krishna
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 66 | - | |
Anthony Marciano
IRC | Investor Relations Contact | - | 17-07-31 |
Lucas Pilipski
PRN | Corporate Officer/Principal | - | 20-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 21-08-31 | |
Richard Pascoe
CHM | Chairman | 60 | 13-02-28 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 18-12-31 |
Brian Lian
BRD | Director/Board Member | 58 | 18-12-31 |
Raj Mehra
CEO | Chief Executive Officer | 64 | 86-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 16,609,128 | 16,335,242 ( 98.35 %) | 0 | 98.35 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
REGNUM CORP. 98.82% | 22,680,000 | 98.82% | 725,760 $ |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |